AstraZeneca PLC Block listing Interim Review (1744Y)
December 01 2017 - 10:00AM
UK Regulatory
TIDMAZN
RNS Number : 1744Y
AstraZeneca PLC
01 December 2017
1 December 2017 15:00 GMT
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed
electronically and provided to an ris.
Date: 1 December 2017
Name of applicant: ASTRAZENECA PLC
--------------------------------------------------- -----------------------------------------------------------------
Name of scheme: ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE
OPTION PLAN; ASTRAZENECA
ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED
SHARE OPTION SCHEME
--------------------------------------------------- -----------------------------------------------------------------
Period of return: From: 1 June 2017 To: 30 November 2017
------------------------- ------------------------ ------------------------- ----------- -------------------------
Balance of unallotted securities under scheme(s)
from previous return: 2,891,656
--------------------------------------------------- -----------------------------------------------------------------
Plus: The amount by which the block scheme(s) has
been increased since the date of the last
return (if any increase has been applied for): 0
--------------------------------------------------- -----------------------------------------------------------------
Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G): 234,464
--------------------------------------------------- -----------------------------------------------------------------
Equals: Balance under scheme(s) not yet
issued/allotted at end of period: 2,657,192
--------------------------------------------------- -----------------------------------------------------------------
Name of contact: CAMILLA WISEMAN
------------------------------ ----------------
Telephone number of contact: 020 3749 5000
------------------------------ ----------------
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
Media Relations
Esra Erkal-Paler UK/Global +44 203 749 5638
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Gonzalo Viña UK/Global +44 203 749 5916
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology; Other +1 240 477 3771
Christer Gruvris Brilinta; Diabetes +44 203 749 5711
Nick Stone Respiratory; Renal +44 203 749 5716
US toll free +1 866 381 7277
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRFSSFLFFWSESE
(END) Dow Jones Newswires
December 01, 2017 10:00 ET (15:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
